PDL Biopharma

Evofem Biosciences is a biopharmaceutical company focused on women's sexual and reproductive health. The company has developed Phexxi, a hormone-free vaginal gel that is the first of its kind approved in the United States for the prevention of pregnancy. Additionally, Evofem is working on EVO100, a vaginal pH regulator designed to prevent the transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Headquartered in San Diego, California, Evofem aims to address unmet needs in the field of women’s health through innovative products.

Evofem Biosciences is a biopharmaceutical company focused on women's sexual and reproductive health. The company has developed Phexxi, a hormone-free vaginal gel that is the first of its kind approved in the United States for the prevention of pregnancy. Additionally, Evofem is working on EVO100, a vaginal pH regulator designed to prevent the transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Headquartered in San Diego, California, Evofem aims to address unmet needs in the field of women’s health through innovative products.

Noden Pharma is a global specialty pharmaceutical company dedicated to acquiring and providing prescription medicines across various therapeutic areas. The company holds exclusive worldwide rights to manufacture, market, and sell Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor used for the treatment of hypertension. Noden Pharma aims to enhance the lives of patients by offering effective medical solutions in international markets.

Kaleo, Inc. is a specialty pharmaceutical company based in Richmond, Virginia, that develops, markets, and sells innovative drug and medical products. Founded in 2008, the company specializes in creating combination drug/device products designed to empower patients in managing their health conditions. Its notable offerings include AUVI-Q, an epinephrine auto-injector for treating severe allergic reactions in infants and small children, and EVZIO, a naloxone injection for opioid overdose. Kaleo's product development emphasizes patient-centric approaches and leverages advanced drug delivery technology to enhance treatment efficacy and safety. The company provides its products through distributors in the United States and Canada and is committed to delivering solutions that improve clinical and economic outcomes for patients and healthcare providers.

Paradigm Spine, LLC is a privately-held medical device company based in New York, specializing in the design, development, and marketing of innovative solutions for spinal diseases. The company focuses on non-fusion spinal implant technology, offering a range of minimally invasive products aimed at treating conditions such as lumbar spinal stenosis and age-related spinal deformities. Key offerings include the Coflex interspinous implant, which is used for facet arthrosis and decompression procedures, as well as the DSS system, a minimally-invasive pedicle-screw based solution. Paradigm Spine emphasizes the development of surgeon-centric and indication-specific products that preserve motion and support natural anatomical function, catering to spine specialists worldwide. Founded in 2002, the company was previously known as Spine Motion, LLC before rebranding in 2005.

Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

Durata Therapeutics is a biopharmaceutical company that specializes in the development and commercialization of treatments for infectious diseases and acute illnesses. Its primary focus is on Dalvance, an intravenous antibiotic designed to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by susceptible gram-positive bacteria in adults. In addition to Dalvance, Durata is advancing two preclinical antibiotic programs. The company was established through a collaboration of several venture capital firms to drive late-stage clinical development of novel antibiotic therapies.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

ESP Pharma is a hospital-focused pharmaceutical company, engages in acquiring and enhancing the marketing of approved specialty therapeutics and late-stage development drugs. It provides therapeutics to physicians, hospitals, and acute-care patients. ESP produces drugs for acute-care hospital use. Its drugs include therapeutics for high blood pressure and angina.